ADVI Analysis: MedPAC September 2024 Meeting
Allison Schneider, MHA
September 17, 2024
MedPAC held a meeting September 5, 2024 (link). The following relevant topics were discussed:
- Context for Medicare payment policy
ADVI Angle
Key takeaways from the September meeting include:
- Context for Medicare payment policy
- Staff provided an overview of the factors contributing to Medicare’s spending growth, as well as the program’s overall financial situation. Commissioners discussed the need for additional data on the Medigap program, a focus on team-based care, and the future impact of GLP-1s on Medicare spending.
This is an abridged and delayed release. Full ADVI Analysis content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.
Allison Schneider, MHA
Director
CEO insights
Related articles
Real analysis from people who’ve been there
The 2026 Rare Disease Reality
Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …
Marc Samuels, JD, MPH
February 26, 2026
AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption
Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …
Marc Samuels, JD, MPH
December 30, 2025
2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption
In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …
Marc Samuels, JD, MPH
December 16, 2025
Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care
CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …
Alicia Silver, MPP
November 21, 2025
Why is Medicare Data Central to IRA Negotiations?
The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …
The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development
Rare diseases impact nearly 1 in 10 people in the US and are largely untreated, with 95 percent lacking FDA-approved …
Tyler Seville, MPA
June 23, 2025
ADVI Analysis: HRSA 340B Covered Entity Audits
Analysis of HRSA 340B Covered Entity Audits Since the 340B Drug Pricing Program began in 1992, covered entities’ participation has …
Prescription Drug Affordability Boards: Access Concerns and Implications for Rare Diseases and Conditions
In recent years, states have increasingly enacted Prescription Drug Affordability Boards (PDABs). While their stated purpose is to increase affordability, …
Allison Schneider, MHA
February 28, 2025
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.